title: De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus.
authors: Urological Institute, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
authors: S
authors: S
authors: Flechner
authors: P
authors: P
authors: Friend
authors: J
authors: J
authors: Campistol
authors: M
authors: M
authors: Weir
authors: F
authors: F
authors: Diekmann
authors: G
authors: G
authors: Russ
mesh_terms: D065095:Calcineurin Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000473:pathology; D009369:Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D011183:Postoperative Complications / Q000453:epidemiology* / Q000517:prevention & control; D011379:Prognosis; D011494:Protein Kinases / Q000502:physiology*; D016032:Randomized Controlled Trials as Topic; D040242:Risk Reduction Behavior; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus